Merck Buys Bio-Techne
Merck agrees to buy Bio-Techne for $73 per share in cash, valuing the company at an enterprise value of $11.3 billion.
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Merck agrees to buy Bio-Techne for $73 per share in cash, valuing the company at an enterprise value of $11.3 billion.
Merck KGaA agrees to acquire Bio-Techne, strengthening its leadership position in life sciences markets
Merck agrees to buy Bio-Techne for $73/shr in cash
Merck agrees to buy Bio-Techne for $73 per share in cash, valuing the company at an enterprise value of $11.3 billion.